MIBG and FDG PET findings in a patient with malignant pheochromocytoma: A significant discrepancy

Shabbir Ezuddin, Christina Fragkaki

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Radionuclide imaging has proven to be very useful when dealing with neuroendocrine tumors and several radiotracers are currently available. One of the most commonly used and widely accepted methods to image pheochromocytomas is I-131 metaiodobenzylguanidine (MIBG) scintigraphy. However, recent studies with positron emission tomography (PET) using 2-[fluorine-18]fluoro-2-deoxy-D- glucose (FDG) in pheochromocytomas have shown that FDG PET imaging can be useful in those pheochromocytomas (usually malignant) that fail to accumulate MIBG. The therapeutic plan of malignant pheochromocytoma can include chemotherapy and/or a high dose of I-131 MIBG, so precise staging and characterization is mandatory for correct management and treatment.

Original languageEnglish (US)
Pages (from-to)579-581
Number of pages3
JournalClinical nuclear medicine
Volume30
Issue number8
DOIs
StatePublished - Aug 1 2005

Keywords

  • FDG PET
  • Malignant pheochromocytoma
  • MIBG scintigraphy
  • Neuroendocrine tumor imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'MIBG and FDG PET findings in a patient with malignant pheochromocytoma: A significant discrepancy'. Together they form a unique fingerprint.

Cite this